|drug1080||Double-Blind NT-I7 Wiki||1.00|
|drug1310||FilmArray PCR on respiratory samples Wiki||1.00|
|D003141||Communicable Diseases NIH||0.07|
There is one clinical trial.
The main purposes of this study is to determine the following in participants with mild coronavirus disease 2019 (COVID-19): - Safety of a single dose of NT-I7 - The immunological effects of NT-I7 on peripheral lymphocyte counts in COVID-19 patients.
Description: Assessment of the number and severity of AEs possibly, probably, or definitely related to study drug evaluated at 7 and 30 days.Measure: Evaluate the safety of a single dose of NT-I7 in a dose escalation fashion Time: Up to approximately 30 days
Description: Assessment of the trajectory of ALC, CD4, CD8, NK, B, and MAIT cells measured at days 7, 14 and 30 after administration of NT-I7 or placebo compared to baseline values.Measure: Evaluate the immunological effects of NT-I7 cumulatively for all doses on peripheral lymphocyte counts in COVID-19 patients. Time: Up to approximately 30 days
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports